Page 2 - Markl Levitt News Today

Highland Park man pleads not guilty to 18 child pornography charges Steven E. Habay Updated 7/15/2021 5:18 PM A 47-year-old Highland Park man pleaded not guilty this week to 18 counts of child pornography and two counts of aggravated battery to a peace officer. Steven E. Habay, of the 1500 block of Lancelot Avenue, appeared before Lake County Judge Mark L. Levitt at a hearing Tuesday.   He faces one count of reproducing child porn and 17 of possession, according to court documents....

Mark L. Levitt will serve as chief judge of the 19th Judicial Circuit Court for a term beginning Jan. 3, 2022.

(1) Independent Data Safety Monitoring Board unanimously recommends continuation of the global Phase 2/3 study of orally-administered opaganib in severe COVID-19 pneumonia based on review of unblinded safety data from the first 255 treated patients The 464-patient global Phase 2/3 COVID-19 study is over 75% enrolled, with completion of enrollment expected in the coming weeks Opaganib potentially minimizes likelihood of resistance due to viral mutations by targeting a human cell component involv...

Credit: RedHill Biopharma Opaganib targets a human cell component involved in viral replication and is therefore expected to be effective against emerging viral variants with mutations in the spike protein Preliminary data from the non-powered U.S. Phase 2 study of opaganib demonstrated safety and positive efficacy data across key primary and secondary endpoints TEL AVIV, Israel and RALEIGH, NC, January 29, 2021, RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty bi...

Share this article Share this article TEL AVIV, Israel and RALEIGH, N.C., Jan. 29, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the independent Data Safety Monitoring Board (DSMB) for the global Phase 2/3 study of opaganib [1] in patients with severe COVID-19, unanimously recommended to continue the study following a pre-scheduled futility review of unblinded efficacy data from the first 135...

Credit: RedHill Biopharma Preliminary data from the non-powered U.S. Phase 2 study of 40 hospitalized patients shows that orally-administered opaganib was safe, with no material safety differences between opaganib and control arms Consistent trends demonstrate greater improvement in reducing oxygen requirement by end of treatment at Day 14 in the opaganib-treated arm across key primary and secondary efficacy outcomes, correlating with clinical improvement as defined by the World Health Organiz...

(2) Preliminary data from the non-powered U.S. Phase 2 study of 40 hospitalized patients shows that orally-administered opaganib was safe, with no material safety differences between opaganib and control arms Consistent trends demonstrate greater improvement in reducing oxygen requirement by end of treatment at Day 14 in the opaganib-treated arm across key primary and secondary efficacy outcomes, correlating with clinical improvement as defined by the World Health Organization (WHO) ordinal sca...

Phase 2/3 COVID-19 study evaluates safety, potential identification of preliminary efficacy signals Top-line data from the 270-patient global Phase 2/3 COVID-19 study expected Q1/2021. Top-line data from the 40-patient U.S. Phase 2 study of opaganib in severe COVID-19 expected in the coming days; this non-powered study was designed to evaluate the safety and potential identification of preliminary efficacy signals in support of the global Phase 2/3 study of opaganib. Opaganib potentially minimi...

22 dicembre 2020 Independent DSMB unanimously recommends continuation of the global Phase 2/3 study of orally-administered opaganib in severe COVID-19 based on review of unblinded safety data from 155 treated patients Top-line data from the 270-patient global Phase 2/3 COVID-19 study expected Q1/2021 Top-line data from the 40-patient U.S. Phase 2 study of opaganib in severe COVID-19 expected in the coming days; this non-powered study was designed to evaluate safety and potential identification...

RedHills Phase 2/3 COVID-19 Study of Opaganib Passes Second DSMB with Unanimous Recommendation to Continue Top-line data from the global Phase 2/3 COVID-19 study expected Q1/2021 Top-line data from the 40-patient U.S. Phase 2 study of opaganib in severe COVID-19 expected in the coming days; this non-powered study was designed to evaluate safety and potential identification of preliminary efficacy signals in support of the global Phase 2/3 study of opaganib Opaganib potentially minimizes likeli...